Figure 5: Primary Efficacy Endpoint of the INOVATE-HF Trial
2019-06-11T07:01:42Z (GMT) by
There was no significant difference in the primary composite outcome of death from any cause or a worsening heart failure event in the vagus nerve stimulation (VNS) treatment arm when compared with the control group (hazard ratio: 1.14; 95% confidence interval: 0.86 to 1.53; p = 0.37). Reproduced with permission from Gold et al. (26). INOVATE-HF = INcrease of VAgal TonE in Heart Failure.